| Methionine is a metabolic dependency of tumor-initiating cells Z Wang, LY Yip, JHJ Lee, Z Wu, HY Chew, PKW Chong, CC Teo, ... Nature medicine 25 (5), 825-837, 2019 | 289 | 2019 |
| Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies HY Chew, PO De Lima, JLG Cruz, B Banushi, G Echejoh, L Hu, ... Cell 180 (5), 895-914. e27, 2020 | 123 | 2020 |
| Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors JJ Sacco, J Kenyani, Z Butt, R Carter, HY Chew, LP Cheeseman, ... Oncotarget 6 (15), 13757, 2015 | 65 | 2015 |
| Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab X He, JL Cruz, S Joseph, N Pett, HY Chew, ZK Tuong, S Okano, G Kelly, ... Oncotarget 9 (15), 12250, 2018 | 13 | 2018 |
| Investigating T Cell Immunity in Cancer: Achievements and Prospects Z Zeng, HY Chew, JG Cruz, GR Leggatt, JW Wells International Journal of Molecular Sciences 22 (6), 2907, 2021 | 12 | 2021 |
| Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit? HY Chew, V Chan, F Simpson, R Dolcetti Cancers 12 (11), 3392, 2020 | 6 | 2020 |
| Scientifically based combination therapies with immuno‐oncology checkpoint inhibitors HY Chew, R Dolcetti, F Simpson British journal of clinical pharmacology 86 (9), 1711-1725, 2020 | 6 | 2020 |
| Publisher Correction: Methionine is a metabolic dependency of tumor-initiating cells. Z Wang, LY Yip, JHJ Lee, Z Wu, HY Chew, PKW Chong, CC Teo, HY Ang, ... Nature medicine 25 (6), 1022-1022, 2019 | 4 | 2019 |
| Germline ERBB3 mutation in familial non-small-cell lung carcinoma: expanding ErbB’s role in oncogenesis AM McInerney-Leo, HY Chew, PL Inglis, PJ Leo, SR Joseph, CL Cooper, ... Human molecular genetics 30 (24), 2393-2401, 2021 | 3 | 2021 |
| Local blockade of tacrolimus promotes T-cell-mediated tumor regression in systemically immunosuppressed hosts M Veitch, K Beaumont, R Pouwer, HY Chew, IH Frazer, HP Soyer, ... Journal for Immunotherapy of Cancer 11 (9), 2023 | 2 | 2023 |
| Arginase-induced cell death pathways and metabolic changes in cancer cells are not altered by insulin HY Chew, G Cvetkovic, S Tepic, JW Wells Scientific Reports 14 (1), 4112, 2024 | | 2024 |
| Abstract B12: Examining EGFR-mediated PI3K/Akt pathway in combination therapy of cetuximab and dynamin inhibition HY Chew, B Panizza, C Cooper, R Dolcetti, J Coward, A McCluskey, ... Molecular Cancer Research 18 (10_Supplement), B12-B12, 2020 | | 2020 |
| Examining EGFR-mediated PI3K/Akt pathway in combination therapy of cetuximab and dynamin inhibition HY Chew, B Panizza, C Cooper, R Dolcetti, J Coward, A McCluskey, ... MOLECULAR CANCER RESEARCH 18 (10), 47-47, 2020 | | 2020 |
| Dynamin inhibition increases monoclonal antibody-dependent cellular cytotoxicity and reverses signalling pathway resistance HY Chew | | 2019 |
| Methionine is a metabolic dependency of tumor-initiating cells (vol 25, pg 825, 2019) Z Wang, LY Yip, JHJ Lee, Z Wu, HY Chew, PKW Chong, CC Teo, ... NATURE MEDICINE 25 (6), 1022-1022, 2019 | | 2019 |
| Germline ERBB3 mutation in familial non-small cell lung carcinoma: expanding the role of the ErbB family in oncogenesis. AM McInerney-Leo, HY Chew, PL Inglis, PJ Leo, SR Joseph, CL Cooper, ... | | |
